{"id":"6mpindividualized","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Pancreatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"6MP is converted intracellularly to active metabolites that interfere with purine metabolism and DNA synthesis, leading to reduced proliferation of lymphocytes and other rapidly dividing cells. The drug is used in individualized dosing regimens, likely guided by thiopurine methyltransferase (TPMT) genotyping or metabolite monitoring to optimize efficacy while minimizing toxicity.","oneSentence":"6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:11.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Inflammatory bowel disease (Crohn's disease, ulcerative colitis)"},{"name":"Autoimmune conditions requiring immunosuppression"}]},"trialDetails":[{"nctId":"NCT00816049","phase":"PHASE3","title":"ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":775}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PuriNethol, Puri-Nethol (6-mercaptopurine)"],"phase":"phase_3","status":"active","brandName":"6MPindividualized","genericName":"6MPindividualized","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation. Used for Acute lymphoblastic leukemia (ALL), Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Autoimmune conditions requiring immunosuppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}